The Oramed transaction could be transformative if executed, providing capital and a high-potential technology platform. However, deteriorating core financials and low cash reserves present near-term risk. Traders should monitor closing of the Oramed deal, execution on new product commercialization, and cash burn in 2026.
Price Chart
Executive Summary
Lifeward reported declining revenue and earnings for Q4 and full-year 2025, with Q4 revenue down 33% YoY to $5.1M and adjusted net loss widening. However, the company secured shareholder approval for a transformative strategic transaction with Oramed, gaining access to oral protein delivery technology and up to $47M in funding, which positions it for a potential turnaround. The deal, combined with cost reductions and strategic acquisitions, aims to drive future growth and achieve cash flow positivity.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $5.1M, down 33% YoY from $7.5M in Q4 2024
- Full-year 2025 revenue declined 14% to $22.0M from $25.7M in 2024
- Adjusted gross margin declined to 32.6% in Q4 2025 from 45.5% in Q4 2024
- Adjusted net loss in Q4 2025 increased 27% to $4.2M from $3.3M in Q4 2024
- Shareholder approval obtained for strategic transaction with Oramed, providing up to $47M in funding
- Lifeward to acquire Oramed’s POD™ oral protein delivery technology; Oramed to take up to 49.99% equity stake
- Company acquired powered upper-body exoskeleton tech to expand ReWalk platform
- Reimbursement expanded with Aetna, Humana, and UnitedHealthcare covering ReWalk under Medicare Advantage
- Cash balance was $2.2M as of December 31, 2025, down from $6.7M in 2024
Financial Impact
Revenue declined by $3.7M (-14%) in 2025; adjusted operating loss increased to $15.1M from $16.6M in 2024; transaction with Oramed could bring up to $47M in non-dilutive funding
Risk Factors
- Low cash balance ($2.2M) raises near-term liquidity concerns
- Core revenue and profitability trends are deteriorating despite cost-cutting
- Oramed transaction is not yet closed and subject to final conditions
- High customer concentration and reliance on reimbursement expansions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258091 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $7.45 $7.11 | ▼ −4.56% | ▼ −2.57% | $5.85 (−21.48%) |
Aug 14, 2026 7w ago | Press Release | $7.45 $7.11 | ▲ +4.56% | ▲ +2.57% | $5.85 (+21.48%) |
Aug 11, 2026 7w ago | EFFECT | $7.57 $7.40 | ▲ +2.18% | ▲ +1.12% | $5.85 (+22.67%) |
Aug 7, 2026 8w ago | Press Release | $7.69 $6.98 | ▼ −9.17% | ▼ −8.78% | $5.85 (−23.88%) |
May 19, 2026 19w ago | 8-K | $6.40 $6.98 | ▲ +9.06% | ▲ +8.08% | $5.85 (−8.59%) |
May 15, 2026 20w ago | 8-K | $6.70 $6.96 | ▼ −3.81% | ▼ −1.69% | $5.85 (+12.69%) |
May 15, 2026 20w ago | Press Release | $6.70 $6.96 | ▼ −3.81% | ▼ −1.69% | $5.85 (+12.69%) |
May 13, 2026 20w ago | EFFECT | $6.63 $6.80 | ▼ −2.56% | ▼ −3.18% | $5.85 (+11.76%) |
May 11, 2026 20w ago | Press Release | $6.40 $6.98 | ▲ +9.09% | ▲ +9.40% | $5.85 (−8.59%) |
Apr 27, 2026 22w ago | S-3 | $7.09 $6.98 | ▲ +1.55% | ▲ +7.02% | $5.85 (+17.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access